REFRACTORY MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test new combo against tough blood cancers
Disease control TerminatedThis early-stage study tested a combination of two chemotherapy drugs, pevonedistat and belinostat, in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had returned or stopped responding to other treatments. The main goal was to find the highest dos…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New drug combo tested for Tough-to-Treat blood cancers
Disease control TerminatedThis study tested a combination of two chemotherapy drugs, venetoclax and azacitidine, for people with high-risk myelodysplastic syndromes (MDS) or related blood cancers. It aimed to find a safe dose and see if the treatment could control the disease, especially for patients whos…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC
-
Targeted drug duo tested for tough blood cancers
Disease control TerminatedThis study tested a combination of two drugs, omacetaxine and venetoclax, for adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or stopped responding to treatment, and who have a specific genetic change called RUNX1. The goal was to find the safest,…
Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC